Trial · NCT01730209
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cognitive ability measured by IQ | 12 months | Assessed by Wechsler scales: Wechsler Preschool and Primary Scale of Intelligence (WPPSI-III NL) and Wechsler Intelligence Scale for Children (WISC-III-NL) |
| Secondary | Autistic features | 12 Months | Assessed by Autism Diagnostic Observation Schedule (ADOS) |
| Secondary | Social and communicational skills | 12 Months | Assessed by social responsiveness scale (SRS) and Dutch Children's Communication Checklist (CCC-2-NL) questionnaires |
| Secondary | Working memory and attention, information processing | 6 and 12 Months | Assessed by Cambridge Neuropsychological Test Automated Battery (CANTAB) |
| Secondary | Visual-motor integration | 12 Months | Assessed by BEERY Visual-Motor Integration (BEERY VMI), grooved pegboard |
| Secondary | Child behavior | 12 Months | Assessed by Child Behavior Checklist (CBCL) and Teacher's Report Form (TRF) questionnaires |
| Secondary | Executive functioning | 12 Months | Assessed by Behavior Rating Inventory of Executive Functioning (BRIEF) questionnaire Dutch version |
| Secondary | Sleeping problems | 12 Months | Assessed by Sleep Disturbance Scale for Children (SDSC) questionnaire |
| Secondary | Child health | 12 Months | Assessed by Child Health Questionnaire Parent Form (CHQ-PF50) questionnaire |
| Secondary | Sensory related difficulties | 12 Months | Assessed by Short Sensory Profile (SSP) questionnaire |
| Secondary | Epilepsy | 12 Months | Comparison of epilepsy frequency during month previous to study start and last month of trial participation. EEG abnormalities |
| Other | School level | 12 Months | Assessed by the school CITO (centraal instituut voor toetsontwikkeling) scores or reading and arithmetic scores |
| Other | Pharmacokinetics | 12 Months | Assessed by measuring trough levels of everolimus |
| Other | Safety | 12 Months | Levels of and abnormalities in blood control values |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01730209/registered